[Atrial fibrillation, comorbidities and new anticoagulants]

Area of Science:

• Cardiology
• Clinical Practice
• Medical Research

Background:

• Atrial fibrillation (AF) is a primary cause of arrhythmia and cerebrovascular disease.
• Comorbidity involves the co-occurrence of active chronic diseases with a target condition.
• Understanding comorbidity burden is crucial for managing AF patients.

Purpose of the Study:

• To compare the comorbidity burden in patients with atrial fibrillation (AF) undergoing interventional versus observational studies.
• To evaluate the implications of comorbidity levels on treatment strategies, particularly anticoagulation in AF.

Main Methods:

• A comparative analysis was conducted on studies from the Medline database.
• Included were four interventional studies and four large observational studies focusing on AF patients.
• Comorbidity burden was assessed as the primary metric for comparison.

Main Results:

• The level of comorbidity was found to be higher in patients included in interventional studies compared to those in large observational studies.
• Cerebrovascular risk was calculated in interventional studies for group comparisons.
• Contrary to expectations, patients in the general population eligible for anticoagulants exhibited a lesser burden of illness.

Conclusions:

• Interventional studies indicate a potentially lower comorbidity burden in AF patients eligible for anticoagulation than previously assumed.
• Recent research on new anticoagulants in the general population supports these findings.
• The risk associated with new anticoagulants may not exceed that observed in pivotal studies.